培美曲塞在晚期非小细胞肺癌姑息性化疗中的作用

The Role of Pemetrexed in Palliative Chemotherapy for Advanced Non-small Cell Lung Cancer

目的研究在晚期非小细胞肺癌(NSCLC)姑息性化疗中应用培美曲塞的效果。方法方便选取2017年2月—2019年12月84例晚期NSCLC患者为对象,随机抽签分为2组,对照组42例在姑息性化疗中应用吉西他滨,观察组42例在姑息性化疗中应用培美曲塞,比较化疗效果。结果观察组化疗中应用培美曲塞后的总有效率为71.43%,不良反应发生率为11.90%,高于对照组总有效率50.00%、不良反应发生率30.95%,差异有统计学意义(χ^(2)=4.043、4.525,P<0.05);观察组治疗结束后CYFRA21-1、CA19-9、CEA水平分别为(2.05±0.84)ng/mL、(27.64±6.38)U/mL、(3.51±1.18)ng/L,均低于对照组(3.06±0.92)ng/mL、(38.42±4.16)U/mL、(5.46±1.38)ng/L,差异有统计学意义(t=5.254、9.173、6.960,P<0.05)。结论NSCLC姑息性化疗中应用培美曲塞可获得更好的短期疗效,更明显控制肿瘤标志物水平,减少化疗相关毒副反应。

Objective To study the effect of pemetrexed in palliative chemotherapy for advanced non-small cell lung cancer(NSCLC).Methods From February 2017 to December 2019,convenient to select 84 patients with advanced NSCLC were randomly divided into 2 groups.42 patients in the control group received gemcitabine during palliative chemotherapy,and 42 patients in the observation group received pemetrexed during palliative chemotherapy,compare the effects of chemotherapy.Results The total effective rate of pemetrexed in the observation group after chemotherapy was 71.43%,the incidence of toxic and side effects was 11.90%,which was higher than the total effective rate of 50.00% in the control group,and the incidence of toxic and side effects was 30.95%,the difference was statistically significant(χ^(2)=4.043,4.525,P<0.05);the levels of CYFRA21-1,CA19-9 and CEA in the observation group after treatment were(2.05±0.84)ng/mL,(27.64±6.38)U/mL,(3.51±1.18)ng/L,all lower than the control group(3.06±0.92)ng/mL,(38.42±4.16)U/mL,(5.46±1.38)ng/L,the difference was statistically significant(t=5.254,9.173,6.960,P<0.05).Conclusion The application of pemetrexed in palliative chemotherapy for NSCLC can achieve better short-term curative effect,more obvious control of tumor marker levels,and reduction of chemotherapy-related side effects.